|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **CANCER TYPE** | **DATASET** | **SUBTYPE** | **ENDPOINT** | **N** | **HR [95% CI-low CI-upp]** | **COX P-VALUE** |
| **Bladder cancer** | GSE5287 |  | OS | 30 | 0.62 [0.22 - 1.75] | 0.3704  |
|  | GSE13507 | Transitional cell carcinoma  | DSS | 165 | 0.90 [0.54 - 1.50] | 0.6817  |
|  | GSE13507 |  | OS | 165 | 1.05 [0.73 - 1.51] | 0.7779  |
| **Blood cancer** | GSE5122 | AML | OS | 58 | 2.11 [0.98 - 4.53] | 0.0568  |
|  | GSE2658 | Multiple myeloma | DSS | 559 | 1.71 [0.91 - 3.22] | 0.0968  |
|  | E-TABM-346 | DLBCL | EFS | 53 | 2.02 [0.77 - 5.35] | 0.1554  |
|  | GSE12417-GPL570 | AML | OS | 79 | 1.35 [0.80 - 2.26] | 0.2586  |
|  | GSE16131-GPL96 | Follicular lymphoma | OS | 180 | 1.40 [0.74 - 2.67] | 0.3041  |
|  | GSE12417-GPL96 | AML | OS | 163 | 1.23 [0.83 - 1.82] | 0.3042  |
|  | E-TABM-346 | DLBCL | OS | 53 | 1.54 [0.54 - 4.39] | 0.4154  |
|  | GSE4475 | B-cell lymphoma | OS | 158 | 1.18 [0.62 - 2.24] | 0.6164  |
|  | GSE8970 | AML | OS | 34 | 1.14 [0.49 - 2.64] | 0.7617  |
| **Brain cancer** | GSE16581 | Meningioma | OS | 67 | **13.02 [1.05 - 161.39]** | **0.0457**  |
|  | GSE4412-GPL96 | Glioma | OS | 74 | 1.84 [0.74 - 4.58] | 0.1886  |
|  | GSE7696 | Glioblastoma | OS | 70 | 0.65 [0.24 - 1.76] | 0.3981  |
|  | GSE4271-GPL96 | Astrocytoma | OS | 77 | 0.98 [0.51 - 1.89] | 0.9520  |
| **Breast cancer** | GSE9195 |  | RFS | 77 | **3.18 [1.45 - 6.98]** | **0.0038**  |
|  | GSE9195 |  | DMFS | 77 | **3.71 [1.51 - 9.12]** | **0.0043**  |
|  | GSE4922-GPL96 |  | DSS | 249 | **2.36 [1.27 - 4.40]** | **0.0067**  |
|  | GSE2034 |  | DMFS | 286 | **1.69 [1.05 - 2.72]** | **0.0323**  |
|  | GSE3494-GPL96 |  | DSS | 236 | **2.33 [1.07 - 5.10]** | **0.0339**  |
|  | GSE1456-GPL96 |  | RFS | 159 | 2.20 [0.96 - 5.05] | 0.0617  |
|  | GSE11121 |  | DMFS | 200 | 2.05 [0.66 - 6.35] | 0.2138  |
|  | GSE1379 |  | RFS | 60 | 0.61 [0.23 - 1.65] | 0.3314  |
|  | GSE1456-GPL96 |  | DSS | 159 | 1.63 [0.60 - 4.44] | 0.3386  |
|  | GSE7378 |  | DFS | 54 | 2.32 [0.36 - 15.07] | 0.3797  |
|  | E-TABM-158 |  | DSS | 117 | 0.73 [0.35 - 1.50] | 0.3862  |
|  | GSE2990 |  | DMFS | 125 | 1.45 [0.49 - 4.26] | 0.4975  |
|  | GSE7390 |  | RFS | 198 | 0.89 [0.61 - 1.28] | 0.5237  |
|  | GSE1378 |  | RFS | 60 | 0.81 [0.41 - 1.61] | 0.5519  |
|  | E-TABM-158 |  | RFS | 117 | 0.84 [0.47 - 1.50] | 0.5561  |
|  | E-TABM-158 |  | OS | 117 | 0.84 [0.47 - 1.50] | 0.5561  |
|  | E-TABM-158 |  | DMFS | 117 | 1.22 [0.63 - 2.35] | 0.5591  |
|  | GSE12093 |  | DMFS | 136 | 1.32 [0.44 - 4.00] | 0.6199  |
|  | GSE2990 |  | RFS | 125 | 1.17 [0.51 - 2.68] | 0.7051  |
|  | GSE2990 |  | DMFS | 54 | 1.09 [0.68 - 1.75] | 0.7154  |
|  | GSE2990 |  | RFS | 62 | 1.06 [0.72 - 1.56] | 0.7700  |
|  | GSE12276 |  | RFS | 204 | 0.96 [0.71 - 1.30] | 0.7983  |
|  | GSE6532-GPL570 |  | RFS | 87 | 1.07 [0.47 - 2.43] | 0.8659  |
|  | GSE6532-GPL570 |  | DMFS | 87 | 1.07 [0.47 - 2.43] | 0.8659  |
|  | GSE7390 |  | DMFS | 198 | 1.02 [0.65 - 1.61] | 0.9149  |
|  | GSE19615 |  | DMFS | 115 | 1.05 [0.22 - 5.06] | 0.9490  |
|  | GSE7390 |  | OS | 198 | 0.99 [0.61 - 1.60] | 0.9622  |
|  | GSE1456-GPL96 |  | OS | 159 | 0.98 [0.40 - 2.43] | 0.9711  |
| **Colorectal cancer** | GSE12945 |  | DFS | 51 | 0.34 [0.07 - 1.78] | 0.2023  |
|  | GSE14333 |  | DFS | 226 | 0.68 [0.35 - 1.33] | 0.2581  |
|  | GSE12945 |  | OS | 62 | 0.61 [0.21 - 1.76] | 0.3646  |
|  | GSE17537 |  | OS | 55 | 0.68 [0.28 - 1.67] | 0.3999  |
|  | GSE17537 |  | DFS | 55 | 1.29 [0.46 - 3.61] | 0.6322  |
|  | GSE17537 |  | DSS | 49 | 0.82 [0.22 - 3.03] | 0.7615  |
|  | GSE17536 |  | DFS | 145 | 0.86 [0.30 - 2.43] | 0.7761  |
|  | GSE17536 |  | DSS | 177 | 0.90 [0.41 - 1.97] | 0.7900  |
|  | GSE17536 |  | OS | 177 | 1.06 [0.53 - 2.10] | 0.8680  |
| **Eye cancer** | GSE22138 | Uveal melanoma | DMFS | 63 | **3.20 [1.68 - 6.09]** | **0.0004**  |
| **Head and neck cancer** | GSE2837 | Squamous cell carcinoma | RFS | 28 | 1.16 [0.87 - 1.55] | 0.3196  |
| **Lung cancer** | jacob-00182-MSK | Adenocarcinoma | OS | 104 | **0.24 [0.08 - 0.72]** | **0.0106**  |
|  | jacob-00182-CANDF | Adenocarcinoma | OS | 82 | 2.62 [0.99 - 6.94] | 0.0536  |
|  | GSE11117 | NSCLC | OS | 41 | 1.74 [0.87 - 3.49] | 0.1174  |
|  | GSE31210 | Adenocarcinoma | RFS | 204 | 2.24 [0.79 - 6.34] | 0.1290  |
|  | GSE4573 | Squamous cell carcinoma | OS | 129 | 0.76 [0.40 - 1.46] | 0.4099  |
|  | GSE8894 | NSCLC | RFS | 138 | 0.87 [0.60 - 1.27] | 0.4701  |
|  | jacob-00182-HLM | Adenocarcinoma | OS | 79 | 1.27 [0.60 - 2.67] | 0.5279  |
|  | GSE17710 | Squamous cell carcinoma | RFS | 56 | 0.76 [0.33 - 1.79] | 0.5358  |
|  | GSE13213 | Adenocarcinoma | OS | 117 | 0.76 [0.32 - 1.85] | 0.5496  |
|  | GSE14814 | NSCLC | OS | 90 | 0.81 [0.37 - 1.77] | 0.6007  |
|  | GSE3141 | NSCLC | OS | 111 | 1.15 [0.68 - 1.94] | 0.6134  |
|  | jacob-00182-UM | Adenocarcinoma | OS | 178 | 1.21 [0.58 - 2.51] | 0.6170  |
|  | GSE17710 | Squamous cell carcinoma | OS | 56 | 0.81 [0.35 - 1.86] | 0.6182  |
|  | GSE31210 | Adenocarcinoma | OS | 204 | 1.30 [0.32 - 5.28] | 0.7120  |
|  | GSE14814 | NSCLC | DSS | 90 | 0.86 [0.36 - 2.05] | 0.7262  |
| **Ovarian cancer** | DUKE-OC |  | OS | 133 | **0.64 [0.46 - 0.89]** | **0.0080**  |
|  | GSE26712 |  | OS | 185 | 0.72 [0.50 - 1.03] | 0.0728  |
|  | GSE26712 |  | DFS | 185 | 0.76 [0.54 - 1.05] | 0.0990  |
|  | GSE8841 |  | OS | 81 | 2.57 [0.59 - 11.24] | 0.2104  |
|  | GSE14764 |  | OS | 80 | 1.42 [0.59 - 3.39] | 0.4350  |
|  | GSE17260 |  | OS | 110 | 0.80 [0.38 - 1.67] | 0.5553  |
|  | GSE9891 |  | OS | 278 | 1.11 [0.72 - 1.70] | 0.6311  |
|  | GSE17260 |  | PFS | 110 | 1.11 [0.65 - 1.88] | 0.7116  |
| **Renal cell carcinoma** | E-DKFZ-1 |  | OS | 59 | **0.18 [0.05 - 0.66]** | **0.0091**  |
| **Skin cancer** | GSE19234 | Melanoma | OS | 38 | **6.90 [1.59 - 29.86]** | **0.0098**  |
| **Soft tissue cancer** | GSE30929 | Liposarcoma | DRFS | 140 | 1.09 [0.46 - 2.59] | 0.8456  |

DFS, disease-free survival; DMFS, distant metastasis-free survival; DRFS, Distant Recurrence Free Survival; DSS, disease-specific survival; EFS, event-free survival; OS, overall survival; PFS, Progression Free Survival; RFS, relapse-free survival.

Bold values indicates *P* < 0.05.

**Supplementary Table 2. Correlation between NAT10 expression and patient prognosis of different cancer in Prognoscan database.**